| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
( Department of Pharmacology, Howard University College of Medicine, Washington, D.C.)
Treatment with three daily doses (3-10 µg/gm each) of thioTEPA inhibited incorporation of radioactive glycine and lysine into protein, of glycine into acid-soluble nucleotides, and of glycine, formate, adenine, and orotic acid into nucleic acids of L-1 mouse tumor in a majority of experiments.
In tumors from mice having other treatment schedules and in livers from all groups no definite change in incorporation of these labeled metabolites was observed.
* Supported by a grant (CY-2854) from the National Cancer Institute, U.S.P.H.S.
Presented at the XXI International Congress of Physiological Sciences at Buenos Aires in August, 1959; an abstract was published in "Abstracts of Communications," p. 220.
Received 8/12/60.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |